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Abstract: The therapeutic options in metastatic renal cell carcinoma have been recently 
expanded by the discovery of the VHL gene, the mutation of which is associated with development 
of clear cell carcinoma, and overexpression of the angiogenesis pathway, resulting in a very 
vascular tumor. This breakthrough in science led to the development of a variety of small 
molecules inhibiting the VEGF-dependent angiogenic pathway, such as sunitinib and sorafenib. 
These agents prolong overall and progression-free survival, respectively. The result was the 
development of robust front-line therapies which ultimately fail and are associated with disease 
progression. In this setting, there existed an unmet need for developing second-line therapies 
for patients with refractory metastatic renal cell carcinoma (MRCC). Everolimus (RAD 001) 
is an oral inhibitor of the mammalian target of rapamycin (mTOR) pathway. The double-blind, 
randomized, placebo-controlled phase III trial of everolimus (RECORD-1) conducted in MRCC 
patients after progression on sunitinib or sorafenib, or both, demonstrated a progression-free 
survival benefit favoring the study drug (4.9 months vs 1.9 months, HR 0.33, 95% CI 0.25 to 
0.43, P  0 0.001). Everolimus thus established itself as a standard of care in the second-line 
setting for patients with MRCC who have failed treatment with VEGF receptor inhibitors.
Keywords: mTOR inhibitor, mammalian target of rapamycin inhibitor, signal transduction 
inhibitor, renal cell carcinoma, targeted therapy
Introduction
Renal cell carcinoma (RCC) is a very aggressive malignancy originating in the renal 
cortex. Annual incidence in the US is approximately 54,000 and 13,000 patients die as 
a result.1 More than 90% of renal tumors are RCC and 85% of RCC are clear cell type. 
The majority (more than 85%) of sporadic RCC is a result of the VHL gene mutation 
(locus 3p25).2 Familial VHL syndrome accounts for a small number of RCC. VHL 
mutation results in the activation of the angiogenesis pathway that, in turn, makes the 
tumor very vascular and dependent on this pathway for survival and proliferation.2
The discovery of the VHL gene and its significance in RCC led to drug development 
based on inhibition of the angiogenic pathway, which in turn led to the introduction 
of various targeted therapies in this disease. Prior to 2005, the standard of care for 
metastatic renal cell carcinoma (MRCC) patients was immunotherapy including inter-
feron (IFN) and interleukin.3,4 The phase II randomized discontinuation trial (RDT) of 
sorafenib, a tyrosine kinase inhibitor (TKI), in MRCC led to establishment of sorafenib 
as a viable option in RCC patients.5 The randomized phase III double-blinded trial 
(TARGETS) of sorafenib vs placebo in the cytokine refractory setting demonstrated 
a doubling of progression-free survival (PFS) favoring sorafenib (5.5 vs 2.8 months; Therapeutics and Clinical Risk Management 2009:5 700
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hazard ratio [HR] −0.44; 95% confidence interval [CI] 0.35 
to 0.55; P  0 .01).6 The phase III trial of sunitinib, another 
small-molecule TKI of the vascular endothelial growth factor 
(VEGF) and other pathways, showed robustness in prolonging 
overall survival (OS) (26.4 vs 21.4 months; HR −0.821; 95% 
CI 0.673 to 1.001; P = 0.051) and PFS (11 vs 5.5 months; 
HR −0.42; 95% CI 0.32 to 0.54; P  0.001) when compared 
head to head with interferon in the first-line setting of MRCC.7 
These results were clinically meaningful and demonstrated 
the effect on OS favoring sunitinib. CALGB-90206 and the 
AVOREN trial demonstrated the efficacy of combining 
bevacizumab with IFN which produces a PFS in the range 
of 8.5 to 10.2 months.8,9 A randomized phase III trial of 
temsirolimus vs IFN vs combination of both (Global ARCC) 
demonstrated the survival benefit in MRCC patients 10.9 vs 
7.3 vs 8.4 months (HR for death 0.73; 95% CI 0.58 to 0.92; 
P = 0.008).10
The above trials established the new standard of care 
in MRCC which included small-molecule TKIs such as 
sunitinib, sorafenib, combination of bevacizumab with IFN, 
and the mTOR (mammalian target of rapamycin inhibitor) 
inhibitor temsirolimus.6–10 These new treatments produce a 
variable frequency of tumor regression, with prolongation 
of PFS and OS, but ultimately the tumor becomes refractory 
to therapy by various mechanisms. Utilization of an 
alternative agent such as the mTOR inhibitor everolimus 
in TKI-refractory RCC is therefore reasonable. There is no 
established molecular or biological evidence of this drug 
working preferentially in tumors which are refractory to 
a TKI, but clearly the use of an agent with an alternative 
mechanism of action was a reasonable strategy.
Molecular targets and mechanism 
of action of everolimus
Everolimus is an orally available inhibitor of mTOR, an 
intra-cytoplasmic serine-threonine kinase which recognizes 
stress response signals in cancer via the PI3K-AKT 
pathway.11 This signal transduction inhibition prevents the 
downstream signaling involved in survival and proliferation 
of tumor cells. The consequences of mTOR signaling 
include phosphorylation of p70 ribosomal S6K1 along 
with the eukaryotic initiation factor 4E binding protein-1 
(4EBP1). The phosphorylation of 4EBP1 results in the 
release of elf-4E, which in turn allows the cap-dependent 
translation of proteins. The mTOR kinase also has some 
control over the angiogenic pathway through the hypoxia-
inducible factor 1 alfa (HIF1α) and VEGF and is linked to 
endothelial proliferation.12,13 Thus the inhibition or signal 
blockade of the mTOR kinase will in turn result in the cutoff 
of signals from the stress response signals, prevention of 
protein translation in cancer cells and also VEGF-dependent 
angiogenic pathway. In theory this is a multi-prong attack 
against RCC.
Clinical trials of everolimus in RCC
Everolimus has been investigated in RCC as a single agent 
as well as in combination with other potent molecules.
everolimus monotherapy
Phase i data
The phase I trial of RAD 001 was conducted by O’Donnell 
et al in a variety of advanced solid tumors. This study aimed 
at reaching the optimal regimen and dosage of everolimus.11 
Patients were treated in 2-part trial. The first part evaluated 
the daily dose of everolimus at 5, 10 and 15 mg per day along 
with the toxicity, antitumor activity, pharmacokinetics and 
the dose-response relationship to S6K1 activity in peripheral 
blood mononuclear cells (PBMCs). The study was comple-
mented by blood and tumor drug levels and S6K1 activity 
study in tumor bearing rats. Part II of the study evaluated 
the weekly doses of 50 mg and 70 mg and the respective 
pharmacokinetics and pharmacodynamics.
A total of 92 patients were treated in the phase I trial. 
Eighteen patients were treated in the weekly regimen in part 1. 
In part II, 37 patients on a weekly schedule and 37 patients 
on a daily schedule were treated. In part I, there was no dose 
limiting toxicity (DLT) reported. The S6K1 activity was 
suppressed 24 hours after the fourth dose in the PBMC and 
the duration of suppression lengthened with higher dosage. 
The daily dosing was able to demonstrate more sustained 
inhibition of S6K1 as opposed to the weekly regimen.
In part II, DLT occurred in 1 out of the 6 patients who 
were in the 50 mg weekly group and none of the 4 patients 
in the 70 mg weekly group. DLT was not observed in 
4 patients who were taking 5 mg daily, but in 1 out of the 
6 patients who were on 10 mg daily dosing. Thus the higher-
dose cohorts were expanded in the weekly and daily regimen. 
The common drug-related adverse events (AE) included 
fatigue (34%), rash (48%) and gastrointestinal toxicities 
(66%). There were 5 serious adverse events resulting in 
4 hospitalizations and 3 patients required discontinuation 
of the therapy. No drug-related mortality was reported by 
the investigators. The elimination half-life was estimated 
to be around 30 ± 8 hours, which was similar to the healthy 
controls. RECIST evaluation demonstrated 4 partial 
responses (PR) and 5 of the 10 RCC patients were progression Therapeutics and Clinical Risk Management 2009:5 701
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free at 6 months. The maximum tolerated dose (MTD) for 
everolimus was not reached in this trial.
Pharmacokinetics/pharmacodynamics
Everolimus is an orally bioavailable inhibitor of the mTOR 
pathway which is metabolized by the CYP3A4 system. The 
PBMC-derived S6K1 suppression was noticed at 24 hours 
in all dose levels after the 4th dose. The length of sustained 
S6K1 suppression was longer with higher doses. The 
minimum dose that would produce a minimum of 7 days 
inhibition of S6K1 was 20 mg.11
Pharmacokinetic profile was studied in 26 out of 
31 patients in the weekly regimen group and 10 patients in 
the daily regimen. In the weekly dose group, steady state 
was achieved by the 2nd week and there was only minimal 
accumulation. It was also observed that Cmax increased in a 
dose-dependent manner at doses 5 mg to 20 mg, but was less 
dose proportional at higher doses. The elimination half-life 
was 30 ± 8 hours at all dose levels.
In the daily dosing group, the steady state of the drug 
was reached within a week and peak concentrations achieved 
within 1 hour in all but 1 patient. The drug level in serum and 
area under the curve (AUC) increased in a dose-dependent 
fashion. The AUC was predicted by the steady state trough 
levels in addition to plasma concentrations and sustained 
inhibition of S6K1 noticed at 20 g in the weekly group 
and 5 mg in the daily group. This correlated well with the 
antitumor activity seen in preclinical models.
Phase ii data
The above results were followed by 2 phase II studies of 
everolimus in renal cell carcinoma. The first phase II study 
was conducted by Jac et al in metastatic RCC patients.14 
The eligibility criteria included predominant clear cell 
histology, measurable disease, adequate organ function, 
absence of central nervous system metastasis, Zubrod 
performance status (ZPS) of 2 or better and no more than 
1 prior treatment. The therapy was RAD-001 given at 10 mg 
daily dose with no interruptions on a 28-day cycle. PET-CT 
was also utilized in addition to RECIST defined criteria 
for response-evaluation which was performed at the end of 
each cycle for 2 cycles. Forty-one patients were enrolled 
and 37 were evaluable for toxicity and response. Median 
age of the cohort was 60 years and 31 were male. Thirty-one 
patients had received prior therapy for MRCC and the ZPS 
was 0 in 23 patients, 1 in 13 patients and 2 in 3 patients. 
There were 12 PR (32%), 19 (51%) had stable disease (SD) 
for 3 months and the rest progressed. Median duration of 
treatment was 8 months and median OS was 11.5 months. 
Most common treatment-related toxicities included mucositis, 
skin rash, pneumonitis, hypophosphatemia, hyperglycemia, 
hypertriglyceridemia and hypercholesterolemia. There was a 
reduction in the FDG uptake in patients who had a response 
or stable disease.
The second study was conducted in patients who had failed 
either sunitinib or sorafenib and had not received 2 prior 
regimens.15 The primary end point was response rate to 
everolimus utilized in the daily dosing schedule of 10 mg 
orally. The eligibility criteria included presence of clear cell 
carcinoma, measurable disease, adequate organ function, 
absence of central nervous system metastasis and good 
performance status. Therapy was administered with everolimus 
at 10 mg daily with no treatment breaks on a 28-day cycle. 
RECIST criteria were used for evaluating the response at 
the end of each 2 cycles. Twenty-two patients were treated 
and majority were male (67%), the median age of the cohort 
was 57 years and all patients had ZPS 0 or 1. Three patients 
withdrew from the study prior to 2 cycles and were excluded 
from the response evaluation. The best response was 3 PR 
(16%), 14 (74%) SD that lasted for 3 months and the rest 
progressed. The median PFS was 5.5 months and the OS 
was beyond 8 months. Commonly seen treatment related 
adverse events included (grade 1 to 2) hypertriglyceridemia 
(73%), hyperglycemia (59%), hypercholesterolemia (64%), 
stomatitis (45%), rash (32%), nausea (27%) and diarrhea 
(18%). Mostly seen grade 3–4 adverse event was pneumonitis 
(27%). This phase II trial demonstrated everolimus as a 
viable agent and its potential in the second-line setting in 
RCC patients.
Phase iii trial of everolimus in metastatic RCC
The promising results of everolimus in the TKI-refractory 
setting of RCC led to the double-blind randomized placebo 
controlled phase III trial of everolimus in metastatic RCC 
patients who progressed on VEGF-targeted therapy.16 
This multi-center trial was conducted at 86 centers in 
Australia, Canada, Europe, Japan, and the USA. The 
patients had metastatic RCC with clear cell component in 
the tumor and had progressed on sunitinib or sorafenib or 
both. Prior treatments allowed also included interferon, 
interleukin, chemotherapy, bevacizumab and radiotherapy. 
More than 95% of the patients in the treatment arm and 
placebo arm had undergone nephrectomy prior to enrol-
ment in this study. The eligibility criteria included pres-
ence of measurable disease, Karnofsky Performance status 
of 70% and adequate solid organ and marrow function. Therapeutics and Clinical Risk Management 2009:5 702
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Exclusion criteria included prior exposure to mTOR 
inhibitors (temsirolimus), untreated brain metastasis or 
uncontrolled co-morbidities. Eligible patients were ran-
domized 2:1 to everolimus vs placebo. Patient stratification 
was based on the Memorial Sloan Kettering Cancer Center 
(MSKCC) prognostic scoring system and also the previous 
anti-RCC therapy (one vs 2 VEGF receptor tyrosine kinase 
inhibitor).17 The treatment included continuous dosing of 
oral everolimus at 10 mg daily or placebo in addition to 
best supportive care. A treatment cycle was defined as 
28 days of treatment and safety evaluation was done every 
2 weeks for 3 cycles and at the end of each cycle after the 
third cycle.
Treatment in both cohorts continued until progression, 
severe toxicity, death or discontinuation. Randomization was 
revealed only at progression and cross-over to open-label 
everolimus was permissible upon progression on placebo. 
Blinded independent central review was utilized for RECIST 
response evaluation.18 PFS was the primary end-point; the 
time from randomization to the earliest sign of progression or 
death. Secondary endpoints were safety, objective response 
rate (ORR), OS, disease-related symptoms and quality of 
life (QOL).
Efficacy was assessed on an intent-to-treat basis 
after randomization. All patients who received a dose 
of everolimus and followed up were assessed for safety. 
QOL was assessed utilizing the European Organization for 
Research and Treatment of Cancer (EORTC) QLQ-C30 
and Functional Assessment of Cancer Therapy Kidney 
Symptom Index-Disease-Related Symptoms (FKSI-DRS) 
questionnaires.19,20
The sample size was calculated based on the prolongation 
of PFS by 50% from 3 months to 4.5 months and a 
risk-reduction of 33% (corresponding to a HR of 0.67). The 
3-month PFS for placebo was assessed based on data from 
the TARGET trial where the placebo treated arm had a PFS 
of  2.8 months after failing prior cytokine based therapy.6 One 
sided cumulative α of 0.025 in the 2:1 random allocation 
calculated the need for 290 events so as to achieve a power 
of 90% in this study. Interim analyses were planned at 30% 
and 60% of the total (290) events and the final analysis at 
290 events. The interim analysis allowed the study to be 
discontinued for reasons of safety, futility, or lack of efficacy. 
Lan DeMets and O’Brien-Fleming spending functions were 
utilized with pre-defined stopping boundaries. The patients 
who did not progress or die at the time of data cutoff were 
censored. Kaplan-Meier method was used for PFS and 
OS estimation.
After screening 554 patients, 410 were randomly 
assigned in a 2:1 ratio to everolimus or placebo. There were 
272 patients in the everolimus arm and 138 in the placebo 
arm. The median age in everolimus arm was 61 and 60 in the 
placebo arm. Nearly 71% in the everolimus group and 79% 
in the placebo group had progressed during prior therapy and 
the median length of treatment was 95 days in everolimus and 
57 days in placebo respectively. Majority (96% in everolimus 
and 95% in placebo) had undergone prior nephrectomy. 
Nearly two-third of patients in each arm had 3 sites of 
disease. The reasons for discontinuation of treatment included 
death, progressive disease, adverse events and withdrawal of 
consent by the patient. At the time of data cutoff, the PFS 
in everolimus assessed by the independent central reviewers 
was significantly longer than placebo arm (HR = 0.33; 95% 
CI 0.25 to 0.43; P  0.001). The best responses observed in 
the two arms were 1% vs 0% PR, 63% vs 32% SD, 19% vs 
46% PD favoring everolimus. In 17% patients on everolimus 
and 22% patients on placebo, disease could not be assessed. 
Median PFS was 4.9 (4 to 5.5 months) months vs 1.9 months 
(1.8 to 1.9 months) favoring everolimus. At 6 months, 
progression-free probability was 26% in patients receiving 
everolimus and 2% in patients receiving placebo.
Pre-defined exploratory and subset analyses demonstrated 
benefit from everolimus in all groups based on age, sex, 
prior VEGF-targeted therapy and geographical region. The 
median OS has not been reached at the time of the data 
cutoff (Table 1). The overall survival data from this trial is 
still being awaited.
No observable difference was evident between the two 
groups with respect to the time to clear-cut deterioration of 
patient-reported outcomes. The evaluation of the FKSI-DRS 
risk score and the EORTC QLQ-C30 score indicated that 
the QOL was sustained in the everolimus group compared 
to placebo. The above scoring system compared various 
factors including physical functioning, global health status/
quality of life, role functioning, emotional functioning, 
cognitive functioning, social functioning and symptoms. 
The above observation favoring the everolimus group was 
irrespective of the increased adverse events seen in the 
active treatment arm.
Adverse events were more frequent in everolimus 
compared to placebo and the most commonly reported 
AE in the study drug arm included stomatitis (44%), 
rash (29%), fatigue (31%), asthenia (33%), anemia 
(92%), hypercholesterolemia (77%), hypertriglyceridemia 
(73%) and hyperglycemia (57%).21 The most commonly 
seen grade 3 AEs in the everolimus arm included stomatitis Therapeutics and Clinical Risk Management 2009:5 703
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(4%), fatigue (5%), pneumonitis (4%), anemia (12%), 
hypercholesterolemia (4%), hyperglycemia (15%), 
lymphopenia (16%) and hypophosphatemia (6%) (Table 2).21 
There were 22 patients who developed non-infectious 
pneumonitis in the everolimus arm compared to none in 
the placebo arm.16 Six out of the 8 patients who developed 
grade 3 pneumonitis had to discontinue the everolimus 
therapy.16 This is a serious adverse event that is defined as the 
radiographic lung change irrespective of signs or symptoms 
(pleural effusion, hypoxia, cough, dyspnea, malaise), in the 
absence of a non-drug cause. Further studies on this adverse 
event are under way.16
The objective response rate was 1% in the everolimus 
arm and none in the placebo arm. Even though everolimus 
was not associated with impressive objective responses, the 
prolongation of PFS demonstrated by this drug was definitely a 
correlation with the increased number of SD observed (Table 3). 
This is an interesting phenomenon, where RECIST-defined 
tumor shrinkage is not necessary for PFS advantage. This is 
an indirect indication of why RECIST-defined tumor evalua-
tion is probably not the best way to assess the response to the 
signal transduction inhibitors, including everolimus.
Everolimus combinations in RCC
The combination of everolimus with another agent is a viable 
option if the second agent targets the signaling in a different 
pathway. This phase II study by Whorf et al utilized the 
combination of bevacizumab with everolimus and enrolled 
patients with advanced RCC into two groups.22 Bevacizumab 
was dosed at 10 mg/kg iv every 2 weeks and everolimus was 
used at 10 mg orally daily until progression. Patients with 
advanced clear cell RCC or metastatic or recurrent RCC, 
with ECOG performance status of 1 or better were enrolled 
in this study. There were two groups of patients based on 
prior treatment: A, no prior treatment or B, prior sunitinib or 
sorafenib. Treatment evaluation was done using the RECIST 
criteria at the end of every 8 weeks.18
Fifty-nine patients (30 to group A and 29 to group B) 
were enrolled. The median age was 65 years with 76% 
having intermediate Motzer prognostic score and 73% with 
prior nephrectomy. There were 42 patients who received 
therapy for at least 8 weeks, 6 patients were non-evaluable 
and 11 were not at the 8-week mark. The best response in the 
evaluable patients (n = 48) was 21% ORR and 69% SD/minor 
response. Toxicities included proteinuria (19% grade 3–4), 
fatigue (9% grade 3–4) mucositis/stomatitis (49% grade 3–4), 
hyperlipidemia (45% grade 3–4), nausea (40% grade 3–4) and 
hypertension (25%). The final results of this study are pending. 
The interim results are suggestive of the feasibility and relative 
safety of the combination of everolimus and bevacizumab.
Report of a phase I trial combining sunitinib and 
everolimus was reported at the 2009 ASCO Annual meeting.23 
Cohorts of patients were enrolled to receive sunitinib at 
37.5 mg in the 4 weeks on/2 weeks off schedule along with 
RAD001 in a daily or weekly regimen.23 The combination 
produced DLT in cohort 4 (sunitinib at 37.5 mg and RAD001 
Table 1 Demographics of the patients included in the phase iii 
trial of everolimus16
Factor Hazard ratio P-value Number
Central review 0.30 0.001 410
investigator review 0.31 0.001 410
MSKCC 
  Favorable 
  intermediate 
  Poor
 
0.35 
0.25 
0.39
 
0.001 
0.001 
0.009
 
118 
231 
61
Prior therapy 
  Sorafenib 
  Sunitinib 
  Both
 
0.29 
0.30 
0.28
 
0.001 
0.001 
0.001
 
119 
184 
107
Age 
  65 
  65
 
0.32 
0.29
 
0.001 
0.001
 
259 
151
Sex 
  Male 
  Female
 
0.29 
0.36
 
0.001 
0.002
 
317 
93
Region 
  USA and Canada 
  europe 
  Japan and Australia
 
0.24 
0.37 
0.10
 
0.001 
0.001 
0.001
 
130 
251 
29
Abbreviation: MSKCC, Memorial Sloan Kettering Cancer Center.
Table 2 Table demonstrating commonly seen grade 3 or 4 toxicities 
(update from the package insert)21
Adverse events Everolimus (N = 274) Placebo (N = 137)
Grade 3 Grade 4 Grade 3 Grade 4
% % % %
Stomatitis 4 1 0 0
Fatigue 5 0 3 1
infections 7 3 1 0
Pneumonitis 4 0 0 0
Anemia 12 1 5 1
Hypercholesterolemia 4 0 0 0
Hyperglycemia 15 1 1 0
Lymphopenia 16 2 5 0
Hypophosphatemia 6 0 0 0Therapeutics and Clinical Risk Management 2009:5 704
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at 30 mg weekly). The severe adverse events included 
endocarditis, gastrointestinal hemorrhage with severe anemia 
and pulmonary embolism. The recommended dose for phase II 
trial of this combination is sunitinib at 37.5 mg in a 4 weeks 
on 2 weeks off fashion with everolimus at 20 mg weekly.23
Ongoing clinical trials of everolimus
After the efficacy and PFS benefit from everolimus in RCC 
was established by the RECORD-1 trial, a series of phase I 
and II clinical trials have been started for evaluating the benefit 
of combining everolimus with various other active agents 
(Table 4). There are trials evaluating the efficacy of everolimus 
in non-clear cell carcinoma and also papillary histology.
Conclusion
Everolimus is a potent orally available mTOR inhibi-
tor, which has shown to be beneficial in the second-line 
setting of metastatic RCC. Everolimus was associated with 
several adverse events, both metabolic and systemic, but 
was tolerated reasonably well by the majority of patients. 
Everolimus produces few RECIST type responses, however, 
tumor shrinkage analysis demonstrates over 70% of patients 
had some degree of shrinkage, and that mostly stable disease 
is produced in this population of refractory patients. The high 
rate of SD translated into a PFS advantage which is double 
that of placebo. This phenomenon may also be partially 
due to the fact that the patients had received more than one 
line of therapy (TKI, cytokines and other therapies) prior 
to trial enrolment and, tumors were refractory to different 
lines of therapy. This is similar to the phenomenon seen 
with sorafenib in the TARGETS trial, where patients were 
treated in the second line, and the response rate to sorafenib 
was 10%, but there was PFS and survival advantage. 
The patients who had prior sunitinib (n = 124) had better 
PFS compared to the placebo (n = 60) (3.88 months vs 
1.84 months; HR 0.34; 95% CI 0.23 to 0.51; P  0.001). 
Similarly the patients who had prior sorafenib (n = 81) 
also did much better than placebo (n = 43) (5.88 months vs 
2.83 months; HR 0.25; 95% CI 0.16 to 0.42; P  0.001). The 
above established everolimus as a choice for treating patients 
with RCC after they fail sunitinib or sorafenib.24
The phase III trial of everolimus was conducted after the 
approval of sorafenib, sunitinib and also temsirolimus for 
patients with RCC. In this scenario the trial was performed 
in the TKI refractory setting, which represented an unmet 
clinical need. The FDA approved everolimus in metastatic 
Table 3 Response and outcome16
Everolimus 
(N = 272)
Placebo 
(N = 138)
Progression-free survival 
  No. of progression events 
  Censored
 
101 (37%) 
171 (63%)
 
90 (65%) 
48 (35%)
Best objective response 
  Partial response 
  Stable disease 
  Progressive disease 
  Could not be assessed
 
3 (1%) 
171 (63%) 
53 (19%) 
45 (17%)
 
0 
44 (32%) 
63 (46%) 
31 (22%)
Overall deaths 42 (15%) 26 (19%)
Table 4 A list of ongoing trials obtained from Clinicaltrials.gov
Combination/phase Clinical trial identifier Center/Sponsor
everolimus and sunitinib/phase ib NCT00788060 Duke University, NC, USA
everolimus and sorafenib/phase i/ii NCT00384969 Univ. of California, 
San Francisco, CA, USA
Bevacizumab + everolimus vs 
bevacizumab + iFN/randomized  
phase ii ReCORD 2
NCT00719264 international multi-center 
trial by Novartis and 
Hoffmann-La Roche
Bevacizumab and everolimus in 
treatment refractory RCC/phase ii
NCT00651482 Stanford University, CA, USA
everolimus and sorafenib 
combination/phase i/ii
NCT00392821 Sarah Cannon Research 
institute, USA
everolimus and vatalanib/phase i NCT00655655 Mayo Clinic, MN, USA
exploratory study evaluating 
fluorodeoxyglucose – Position 
emission Tomography as a Predictive 
Marker for Therapy with everolimus 
in Metastatic Renal Cell Cancer
NCT00529802 University of Chicago, iL, USA
Abbreviations: iFN, interferon;  RCC, renal cell carcinoma.Therapeutics and Clinical Risk Management 2009:5 705
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RCC patients who are refractory to sunitinib or sorafenib. 
The increased number of SD and PFS advantage seen in 
the everolimus arm proved that RECIST-defined tumor 
shrinkage is probably not necessary for PFS benefit. It is also 
demonstrating an unmet need for functional imaging studies 
in RCC patients treated with signal transduction inhibitors 
like everolimus, and thus changing the standard of evaluation 
from the traditional RECIST evaluation to a more meaning-
ful evaluation that would correlate with the activity of the 
tumors. Per the RECIST evaluation this could be further 
characterized as high disease stabilization effect, as in the 
case of sorafenib. The changes observed in the FDG PET CT 
after cycle 2 (phase II trial) in patients who had a PR or SD 
could mean that it is more of a meaningful way of evaluating 
response to drugs that block signaling. This could also mean 
that the RECIST defined SD may indeed be contributing 
to the potential progression-free survival benefit from this 
agent. But the above needs to be validated by larger studies. 
The revised RECIST (ver 1.1) also allows the judicious use 
of FDG PET-CT to complement CT findings.25
The adverse events were more frequent in the everolimus 
arm compared to the placebo group. The adverse events were 
unique in the sense that there were metabolic adverse events 
like hyperlipidemia, hyperglycemia, hypophosphatemia etc in 
addition to the class-specific non-infectious pneumonitis.
In addition, the QOL of advanced RCC patients treated 
with everolimus was maintained, independent of the adverse 
events produced by everolimus. This means that everolimus 
may be a good choice in patients with advanced disease where 
the goals could be re-set to improvement in the quality of life 
and disease stabilization with PFS benefit rather than tumor 
shrinkage. This drug is in the same class as temsirolimus, but 
its advantage is that it is orally dosed opposed to the weekly 
iv dosing of temsirolimus, which could be cumbersome. For 
the above reasons, everolimus was approved in advanced 
RCC patients, who failed prior TKI-based therapy.
Everolimus is an orally bioavailable agent, whereas 
temsirolimus is an intravenous prodrug. Both agents are 
mTOR inhibitors, differences relate to their pharmacodynamic 
and pharmacokinetic properties. The differences in their 
indications in RCC relate to study design and patient 
populations in which the respective trials were conducted.
There should also be front-line trials of everolimus in 
advanced RCC as it has proven to be an effective second-line 
agent. This drug might bring forth more responses, if tried 
in the front-line setting. The activity of everolimus in 
the front-line setting may be much better than in the 
TKI-1 setting, due to the difference in biology of the disease 
between treatment-naive and TKI-refractory settings. The 
various combination trials of everolimus with agents which 
work in pathways other than mTOR signaling would be worth 
waiting for. Phase IV studies of everolimus for assessing the 
safety in large populations are underway.
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